Generation Bio, a preclinical biotech developing gene therapies for rare diseases, raised $200 million by offering 10.5 million shares at $19, the high end of the revised range of $18 to $19. The company offered 0.5 million more shares than anticipated after upwardly revising its share offering and range earlier today. At pricing, the company commands a fully diluted market cap of $916 million.
Generation Bio plans to list on the Nasdaq under the symbol GBIO. J.P. Morgan, Jefferies, and Cowen acted as lead managers on the deal.
